The role of platelets CD40 ligand (CD154) in acute coronary syndromes

El-Makrem, Mona A. Abu; Mahmoud, Yehia A.-G.; Sayed, Douaa; Nassef, Noussa M.; El-Kader, Samir S. Abd; Zakhary, Madiha; Ghazaly, Taghreed; Matta, Ragaa Abdelshaheed

doi:10.1016/j.thromres.2009.06.028

Cited by 14 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, patients with UA who needed coronary angioplasty or who had recurrence of angina were characterised by the highest CD40L expression on platelets (98). A significant positive correlation has been found between platelet CD40L expression, endothelial dysfunction and circulating levels of oxidised low-density lipoproteins, C-reactive protein and fibrinogen (99). As surface expression of CD40L is tightly related to circulating soluble CD40L levels (101), the latter assay has been more extensively used in the clinical setting because of its advantages as compared to flow-cytometry, including limited costs and higher degree of standardisation.…”

Section: Cd40-cd40l Systemmentioning

confidence: 99%

Biomarkers of platelet activation in acute coronary syndromes

Ferroni

Riondino²,

Vazzana

et al. 2012

Thromb Haemost

View full text Add to dashboard Cite

The most convincing evidence for the participation of platelets in arterial thrombosis in humans comes from studies of platelet activation in patients with acute coronary syndromes (ACS) and from trials of antiplatelet drugs. Both strongly support the concept that repeated episodes of platelet activation over the thrombogenic surface of a vulnerable plaque may contribute to the risk of death from coronary causes. However, the relation of in vivo platelet activation and adverse clinical events to results of platelet function tests remains largely unknown. A valuable marker of in vivo platelet activation should be specific, unaltered by pre-analytical artefacts and reproducibly measured by easily performed methods. This article describes current biomarkers of platelet activation in ACS, reviews their advantages and disadvantages, discusses their potential pitfalls, and demonstrates emerging data supporting the positive clinical implications of monitoring in vivo platelet activation in the setting of ACS.

show abstract

Section: Cd40-cd40l Systemmentioning

confidence: 99%

Biomarkers of platelet activation in acute coronary syndromes

Ferroni

Riondino²,

Vazzana

et al. 2012

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…That is the case of the platelet surface P-selectin or CD40 ligand (CD40-L or CD154) [22]. A recent study has shown patients with acute myocardial infarction (MI) and unstable angina have higher levels of platelet CD154 and P-selectin as compared to those with stable angina or healthy volunteers [23]. Nevertheless, the more direct, biology-based approach to platelet biomarkers may rest with an ability to characterize them in either a state of interaction with other cells (e.g.…”

Section: Discussionmentioning

confidence: 99%

Proteins Involved in Platelet Signaling Are Differentially Regulated in Acute Coronary Syndrome: A Proteomic Study

et al. 2010

View full text Add to dashboard Cite

BackgroundPlatelets play a fundamental role in pathological events underlying acute coronary syndrome (ACS). Because platelets do not have a nucleus, proteomics constitutes an optimal approach to follow platelet molecular events associated with the onset of the acute episode.Methodology/Principal FindingsWe performed the first high-resolution two-dimensional gel electrophoresis-based proteome analysis of circulating platelets from patients with non-ST segment elevation ACS (NSTE-ACS). Proteins were identified by mass spectrometry and validations were by western blotting. Forty protein features (corresponding to 22 unique genes) were found to be differentially regulated between NSTE-ACS patients and matched controls with chronic ischemic cardiopathy. The number of differences decreased at day 5 (28) and 6 months after the acute event (5). Interestingly, a systems biology approach demonstrated that 16 of the 22 differentially regulated proteins identified are interconnected as part of a common network related to cell assembly and organization and cell morphology, processes very related to platelet activation. Indeed, 14 of those proteins are either signaling or cytoskeletal, and nine of them are known to participate in platelet activation by αIIbβ3 and/or GPVI receptors. Several of the proteins identified participate in platelet activation through post-translational modifications, as shown here for ILK, Src and Talin. Interestingly, the platelet-secreted glycoprotein SPARC was down-regulated in NSTE-ACS patients compared to stable controls, which is consistent with a secretion process from activated platelets.Conclusions/SignificanceThe present study provides novel information on platelet proteome changes associated with platelet activation in NSTE-ACS, highlighting the presence of proteins involved in platelet signaling. This investigation paves the way for future studies in the search for novel platelet-related biomarkers and drug targets in ACS.

show abstract

“…70 However, there is still poor evidence for its use in clinical practice as a diagnostic biomarker 71,72 and contrasting evidence for its use as a prognostic biomarker. [73][74][75][76] Copeptin Also known as CT-proAVP, copeptin is the C-terminal portion of arginine-vasopressin precursor (AVP or anti-diuretic hormone). Copeptin is a very stable glycopeptide released together with AVP during common precursor (named prepro-vasopressin) processing by the posterior pituitary gland.…”

Section: Cd40 Ligandmentioning

confidence: 99%

Biomarkers in the prediction and management of acute coronary syndromes: current perspectives

Gilardi¹,

Iacomini²,

Marsiliani³

et al. 2014

RRCC

View full text Add to dashboard Cite

A large branch of research has focused on the search for biomarkers for early detection of myocardial cell injuries. Most of these studies have evaluated patients presenting to the emergency department, underlining the need for an ideal biomarker for rapid recognition of acute coronary syndrome (ACS). In the recent past, diagnosis of ACS in the emergency department has been based mostly on clinical information and electrocardiographic findings, and markers of generic cell damage have been used to support clinical suspicion. Over the last few years, the role of markers has taken up increasingly more space in non-life-threatening conditions, confining the clinical examination of the patient to the mere waiting for results of blood tests after the electrocardiograph. Currently, the biomarkers most widely used for the diagnosis of ACS are cardiac troponins. Since their introduction into clinical practice, several generations of commercial cardiac troponin assays have been validated in analytical and clinical trials. Development of newer high-sensitivity assays seems to have improved the value of cardiac troponin as both a diagnostic and risk indicator. Several other biomarkers of ACS apart from cardiac troponin have been investigated, but most still require validation in further studies. Among these, pregnancy-associated plasma protein-A, ischemia-modified albumin, and heart-type fatty acid binding protein seem to be the most promising markers under investigation for their possible usefulness in the emergency department setting for early diagnosis of ACS. In conclusion, a multimarker approach could be the future of research. In this review, we highlight the old and new markers, especially the most studied and widely used in clinical practice in recent years, particularly those that can help the clinician to make a rapid and confident diagnosis of ACS.

show abstract

The role of platelets CD40 ligand (CD154) in acute coronary syndromes

Cited by 14 publications

References 29 publications

Biomarkers of platelet activation in acute coronary syndromes

Biomarkers of platelet activation in acute coronary syndromes

Proteins Involved in Platelet Signaling Are Differentially Regulated in Acute Coronary Syndrome: A Proteomic Study

Biomarkers in the prediction and management of acute coronary syndromes: current perspectives

Contact Info

Product

Resources

About